Ignite Creation Date:
2024-10-25 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06610669
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-20
Brief Title:
The Prevalence of Hyper-Lpa-Emia in the PMMHRI-Lpa Registry
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Prevalence Patients Characteristics and Hyper-Lpa-Emia Risk Factors in the Polish Population The Polish Mothers Memorial Hospital Research Institute Lipoproteina Registry
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The PMMHRI-Lpa-Registry is a non-interventional single-center registry conducted in the Polish Mothers Memorial Hospital Research Institute PMMHRI The PMMHRI-Lpa-Registry was established in January 2022 Since then all consecutive patients of the Department of Cardiology and Adult Congenital Heart Diseases Department of Endocrinology and outpatient cardiology and endocrinology clinics with the measured Lpa concentration have been included
Detailed Description:
The PMMHRI-Lpa-Registry is a non-interventional single-center registry conducted in Polands 2nd largest supra-regional hospital - the Polish Mothers Memorial Hospital Research Institute PMMHRI The PMMHRI-Lpa-Registry was established in January 2022 Since then all consecutive patients of the Departments of Cardiology Endocrinology and outpatient cardiology and endocrinology clinics have been included The indications for Lpa measurement in the registry are based on the 2021 Polish Lipid Guidelines and new Polish recommendations on the management of elevated Lpa 2024 Lpa was determined using Sentinels Lpa Ultra an Immunoturbidimetric quantitative test Sentinel Milan Italy and the results are presented in mgdl
The following information was collected from the patients medical records demographic parameters relevant comorbidities concomitant medications including lipid-lowering therapy status anticoagulation status smoking status post hoc calculated cardiovascular risk score and laboratory parameters including ie Lpa and lipids profile
The following information was collected from the patients medical records demographic parameters relevant comorbidities concomitant medications including lipid-lowering therapy status anticoagulation status smoking status post hoc calculated cardiovascular risk score and laboratory parameters including ie Lpa and lipids profile
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None